Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Riely, G. J. [1 ]
Evans, T. L. [2 ]
Salgia, R. [3 ]
Ou, S. I. [4 ]
Gettinger, S. N. [5 ]
Otterson, G. A. [6 ]
Lanzalone, S. [7 ]
Polli, A. [8 ]
Shaw, A. T. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] Yale Univ, Sch Med, New Haven, CT USA
[6] Ohio State Univ, Columbus, OH 43210 USA
[7] Pfizer Italy Srl, Milan, Italy
[8] Pfizer Inc, Milan, Italy
[9] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S204 / S204
页数：1
相关论文
共 50 条
  • [1] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Kim, D.
    Ahn, M.
    Yang, P.
    Liu, X.
    De Pas, T.
    Crino, L.
    Lanzalone, S.
    Polli, A.
    Shaw, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 402 - 402
  • [3] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
    Kim, D. -W.
    Ahn, M. -J
    Shi, Y.
    De Pas, T. M.
    Yang, P. -C
    Riely, G. J.
    Crino, L.
    Evans, T. L.
    Liu, X.
    Han, J. -Y.
    Salgia, R.
    Lanzalone, S.
    Polli, A.
    Iyer, S.
    Shaw, A. T.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
  • [4] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
    Ferreira, Carlos G.
    Barrios, C.
    Shaw, Alice T.
    Shi, Yuankai
    De Pas, Tommaso M.
    Yang, Pan C.
    Riely, Greg J.
    Crino, Lucio
    Iyer, Shrividya
    Polli, Anna
    Lanzalone, Silvana
    Kim, Dong W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S108
  • [6] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [7] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [8] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Ahn, M-J
    Crino, L.
    Solomon, Ben
    Zhou, Caicun
    Ou, Sai-hong I.
    Selaru, P.
    Cohen, D. P.
    Bartlett, C. H.
    Kim, Dong-wan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
  • [9] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [10] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
12345